Diagnostic consequences of a new category of anxious depression and a reduced duration requirement for anxiety symptoms in the ICD-11 PHC.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 02 2019
Historique:
received: 14 05 2018
revised: 06 08 2018
accepted: 05 10 2018
pubmed: 28 10 2018
medline: 26 3 2019
entrez: 28 10 2018
Statut: ppublish

Résumé

A new diagnosis of anxious depression (AD), characterized by both depressive and anxious symptoms at case level, has been proposed for the classification of mental disorders for primary care for ICD-11 (ICD-11 PHC). The ICD-11 PHC proposes a duration requirement for anxiety symptoms of 2 weeks, in line with the requirement for depressive symptoms. This study examined diagnostic assignment under ICD-11 PHC as compared to the previous classification, the ICD-10 PHC, and the relationship of anxiety duration to disability and suicidal ideation. Primary care physicians in five countries referred patients based on either perceived psychological distress or distressing somatic symptoms to a research assistant who administered a computer-guided diagnostic interview. Complete data were obtained for 2279 participants. Under ICD-11 PHC 47.7% participants received a diagnosis of AD and had greater disability than other diagnostic groups. Under ICD-10 PHC, in addition to meeting requirements for depressive episode, most of these patients met requirements for either generalized anxiety disorder (41.5%) or mixed anxiety and depressive disorder (45.4%). One third of individuals diagnosed with AD had anxiety durations between 2 weeks and 3 months and presented as much disability and suicidal ideation as individuals with longer anxiety durations. The study was not designed to establish prevalence of these conditions. The proposed ICD-11 PHC encourages early identification and management of significant anxiety symptoms in primary care, particularly when these co-occur with depression. This study provides support for the clinical relevance of these symptoms and the importance of early identification.

Sections du résumé

BACKGROUND
A new diagnosis of anxious depression (AD), characterized by both depressive and anxious symptoms at case level, has been proposed for the classification of mental disorders for primary care for ICD-11 (ICD-11 PHC). The ICD-11 PHC proposes a duration requirement for anxiety symptoms of 2 weeks, in line with the requirement for depressive symptoms. This study examined diagnostic assignment under ICD-11 PHC as compared to the previous classification, the ICD-10 PHC, and the relationship of anxiety duration to disability and suicidal ideation.
METHODS
Primary care physicians in five countries referred patients based on either perceived psychological distress or distressing somatic symptoms to a research assistant who administered a computer-guided diagnostic interview. Complete data were obtained for 2279 participants.
RESULTS
Under ICD-11 PHC 47.7% participants received a diagnosis of AD and had greater disability than other diagnostic groups. Under ICD-10 PHC, in addition to meeting requirements for depressive episode, most of these patients met requirements for either generalized anxiety disorder (41.5%) or mixed anxiety and depressive disorder (45.4%). One third of individuals diagnosed with AD had anxiety durations between 2 weeks and 3 months and presented as much disability and suicidal ideation as individuals with longer anxiety durations.
LIMITATIONS
The study was not designed to establish prevalence of these conditions.
CONCLUSION
The proposed ICD-11 PHC encourages early identification and management of significant anxiety symptoms in primary care, particularly when these co-occur with depression. This study provides support for the clinical relevance of these symptoms and the importance of early identification.

Identifiants

pubmed: 30368071
pii: S0165-0327(18)30980-7
doi: 10.1016/j.jad.2018.10.082
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-125

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Carolina Ziebold (C)

Universidade Federal de São Paulo, Brazil.

Jair J Mari (JJ)

Universidade Federal de São Paulo, Brazil.

David P Goldberg (DP)

Institute of Psychiatry, King's College London, United Kingdom.

Fareed Minhas (F)

Institute of Psychiatry, Rawalpindi, Pakistan.

Bushra Razzaque (B)

Institute of Psychiatry, Rawalpindi, Pakistan.

Sandra Fortes (S)

Universidade do Estado do Rio de Janeiro, Brazil.

Rebeca Robles (R)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico DF, Mexico.

Tai Pong Lam (TP)

University of Hong Kong, People's Republic of China.

Julio Bobes (J)

University of Oviedo, CIBERSAM, Oviedo, Spain.

Celso Iglesias (C)

University of Oviedo, CIBERSAM, Oviedo, Hospital Valle del Nalon, Langreo, Spain.

José Ángel García (JÁ)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico DF, Mexico.

Geoffrey M Reed (GM)

Department of Mental Health and Substance Abuse,World Health Organization; Global Mental Health Program, Department of Psychiatry, Columbia University Medical Center, Unit 9, Rom 5808, 1051 Riverside Drive, New York, NY 10032 USA. Electronic address: gmr2142@cumc.columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH